BMJ Open Gastroenterology, 12(1), e001704
64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
But they arent a product you should take and expect to get results without putting in the work
Liraglutide vs Semaglutide: The Molecular Difference Liraglutide (Saxenda): First-generation GLP-1 agonist for weight loss Approximately 97% amino acid similarity to natural GLP-1 Half-life of approximately 13 hours Requires daily injection to maintain blood levels Semaglutide (Ozempic, Wegovy): Second-generation GLP-1 agonist Modified structure for greater potency and longer action Half-life of approximately 7 days Weekly injection maintains stable blood levels The structural modifications in semaglutide make it bind more effectively to GLP-1 receptors and resist breakdown longer
Not all possible interactions are listed here